EP2900691A4 - Generation of new pancreatic beta cells - Google Patents

Generation of new pancreatic beta cells

Info

Publication number
EP2900691A4
EP2900691A4 EP13841793.6A EP13841793A EP2900691A4 EP 2900691 A4 EP2900691 A4 EP 2900691A4 EP 13841793 A EP13841793 A EP 13841793A EP 2900691 A4 EP2900691 A4 EP 2900691A4
Authority
EP
European Patent Office
Prior art keywords
generation
beta cells
pancreatic beta
new pancreatic
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13841793.6A
Other languages
German (de)
French (fr)
Other versions
EP2900691A1 (en
Inventor
Claresa Levetan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/662,209 external-priority patent/US8911776B2/en
Priority claimed from US13/662,245 external-priority patent/US9511110B2/en
Priority claimed from US13/662,253 external-priority patent/US9133440B2/en
Priority claimed from US13/662,232 external-priority patent/US20140120560A1/en
Application filed by Individual filed Critical Individual
Publication of EP2900691A1 publication Critical patent/EP2900691A1/en
Publication of EP2900691A4 publication Critical patent/EP2900691A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/474—Pancreatic thread protein; Reg protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP13841793.6A 2012-09-27 2013-09-26 Generation of new pancreatic beta cells Withdrawn EP2900691A4 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261706225P 2012-09-27 2012-09-27
US13/662,209 US8911776B2 (en) 2012-09-27 2012-10-26 Generation of new pancreatic beta cells
US13/662,245 US9511110B2 (en) 2012-09-27 2012-10-26 Generation of new pancreatic beta cells
US13/662,253 US9133440B2 (en) 2012-09-27 2012-10-26 Generation of new pancreatic beta cells
US13/662,232 US20140120560A1 (en) 2012-10-26 2012-10-26 Generation of new pancreatic beta cells
PCT/US2013/061947 WO2014052611A1 (en) 2012-09-27 2013-09-26 Generation of new pancreatic beta cells

Publications (2)

Publication Number Publication Date
EP2900691A1 EP2900691A1 (en) 2015-08-05
EP2900691A4 true EP2900691A4 (en) 2016-04-20

Family

ID=50388965

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13841793.6A Withdrawn EP2900691A4 (en) 2012-09-27 2013-09-26 Generation of new pancreatic beta cells

Country Status (5)

Country Link
EP (1) EP2900691A4 (en)
JP (1) JP2015533821A (en)
AU (1) AU2013323462A1 (en)
CA (1) CA2886442A1 (en)
WO (1) WO2014052611A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104614523B (en) * 2014-12-19 2016-09-21 成都永安制药有限公司 Mycobacterium tuberculosis TB-SA abzyme linked immunosorbent assay (ELISA) kit and preparation method thereof
WO2017063657A1 (en) * 2015-10-14 2017-04-20 Phlogo Aps Il1ra-derived peptide antagonist
US20190142901A1 (en) * 2017-11-16 2019-05-16 Claresa Levetan Compositions and methods for treating or preventing type 1 diabetes using a biologic response modifier in combination with one or more islet or beta cell regeneration or replacement therapies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009029847A1 (en) * 2007-08-30 2009-03-05 Curedm, Inc. Compositions and methods of using proislet peptides and analogs thereof
WO2009049222A1 (en) * 2007-10-12 2009-04-16 Curedm, Inc. Compositions and methods of using the human proislet peptide receptor
EP2295066A1 (en) * 2005-05-25 2011-03-16 CureDM Group Holdings, LLC Peptides, derivatives and analogs thereof, and methods of using same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834590A (en) * 1995-02-22 1998-11-10 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Ingap protein involved in pancreatic islet neogenesis
AU6049899A (en) * 1998-09-17 2000-04-17 Trustees Of Columbia University In The City Of New York, The Trex, a novel gene of traf-interacting ext gene family and diagnostic and therapeutic uses thereof
US20040132644A1 (en) * 2001-10-16 2004-07-08 The Procter & Gamble Company Composition and method for treating diabetes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2295066A1 (en) * 2005-05-25 2011-03-16 CureDM Group Holdings, LLC Peptides, derivatives and analogs thereof, and methods of using same
WO2009029847A1 (en) * 2007-08-30 2009-03-05 Curedm, Inc. Compositions and methods of using proislet peptides and analogs thereof
WO2009049222A1 (en) * 2007-10-12 2009-04-16 Curedm, Inc. Compositions and methods of using the human proislet peptide receptor

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LEVETAN CLARESA S ET AL: "Discovery of a human peptide sequence signaling islet neogenesis", ENDOCRINE PRACTICE, AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGY, US, vol. 14HIP derived from human Reg3a : 14 aa long : IGL, no. 9, 1 December 2008 (2008-12-01), pages 1075 - 1083, XP002513221, ISSN: 1530-891X *
RAHUL KAPUR ET AL: "Short-term effects of INGAP and Reg family peptides on the appearance of samll beta-cells clusters in non-diabetic mice", ISLETS, vol. 4, no. 1, 1 January 2012 (2012-01-01), pages 40 - 48, XP002755391, DOI: 10.4161/isl.18659 *
ROSENBERG L ET AL: "A pentadecapeptide fragment of islet neogenesis-associated protein increases beta-cell mass and reverses diabetes in C57BL/6J mice", ANNALS OF SURGERY, J.B. LIPPINCOTT COMPANY, PHILADELPHIA, US, vol. 240, 1 January 2004 (2004-01-01), pages 875 - 884, XP002419918, ISSN: 0003-4932, DOI: 10.1097/01.SLA.0000143270.99191.10 *
See also references of WO2014052611A1 *

Also Published As

Publication number Publication date
EP2900691A1 (en) 2015-08-05
CA2886442A1 (en) 2014-04-03
AU2013323462A1 (en) 2015-04-23
JP2015533821A (en) 2015-11-26
WO2014052611A1 (en) 2014-04-03

Similar Documents

Publication Publication Date Title
HK1199905A1 (en) Culturing of mesenchymal stem cells
IL236537A0 (en) Conversion of biomass
EP2872184A4 (en) Use of cart19 to deplete normal b cells to induce tolerance
EP2844738A4 (en) Generating pluripotent cells de novo
HK1209560A1 (en) Mechanism for discovery of small cells
EP2890631A4 (en) Hydrogen generation assemblies
SG11201503579RA (en) Cell culture med
EP2820125A4 (en) Expansion of alloantigen-reactive regulatory t cells
EP2717924A4 (en) Modulation of pancreatic beta cell proliferation
GB201204905D0 (en) Transport of cells
EP2911230A4 (en) Cell
HK1221250A1 (en) Structure for culturing cells
SG10201700670WA (en) Cell culture
EP2859356A4 (en) Pathways characterization of cells
EP2831949A4 (en) Sodium-oxygen cells
IL237118A0 (en) Methods of isolating distinct pancreatic cell types
EP2830131A4 (en) Cell structure of fuel cell
IL239484A0 (en) Agents for eliminating tumour-initiating cells
EP2694705A4 (en) Microfrabication of tunnels
HK1214601A1 (en) New bis-iridium-complexes for manufacturing of ecl-labels ecl---
EP2900691A4 (en) Generation of new pancreatic beta cells
EP2807622A4 (en) Best-deal list generation
EP2912694A4 (en) Methods of forming solar cells
GB201211873D0 (en) Cell culture
GB201217806D0 (en) Clock distribution scheme

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150423

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20160321

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 19/00 20060101ALI20160314BHEP

Ipc: G01N 33/53 20060101ALI20160314BHEP

Ipc: A61K 38/17 20060101ALI20160314BHEP

Ipc: C07K 16/28 20060101ALI20160314BHEP

Ipc: C07K 14/47 20060101AFI20160314BHEP

17Q First examination report despatched

Effective date: 20170524

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20171205